Bone marrow mononuclear cells (BMMCs) are a heterogeneous population of primary cells that are derived from the adult bone marrow. These mononuclear cells include lymphocytes, monocytes, hematopoietic stem cells, and hematopoietic progenitor cells. The bone marrow mononuclear cells also include a population of mesenchymal stromal cells and these cells are isolated from human adult bone marrow using the process of density gradient separation in biosafety labs under the technical supervision of cell culture experts.
Recently, Bone Marrow-Derived Mononuclear Cells (BM-MNCs) have been in the research and clinical spotlight for showing the potential to treat a variety of diseases including neurological disorders, ischemic vascular disease, peripheral arterial disease, and cardiovascular diseases. There are various advantages to using bone marrow cells. The first one is the abundance of the cells which finely contributes to the shortening of the processing time as there is very minimal need for cell expansion, and the second major advantage is the potential of these cells to modulate immune response and angiogenesis. Besides these advantages, bone marrow mononuclear cells have a stem cell population that can differentiate into various cell lineages, including endothelial cells and smooth muscle cells. In terms of therapeutics, researchers can take either way: implanting undifferentiated cells or implanting specific lineage differentiated cells.
What factors do make these cells so research-friendly and do they really show therapeutic potential in reality? BMMCs have regenerative and repair capabilities and are a heterogeneous population of cells having a single nucleus, like hematopoietic progenitor & hematopoietic stem cells, immature monocytes, and lymphocytes. Hematopoietic stem cells have shown the ability to self-renew and can differentiate into a variety of adult cell types. Studies that focus on using stem cells as regenerative therapy have shown great success in animal models and patient case reports for diseases like osteoarthritis, cardiovascular disease, multiple sclerosis, diabetes, Alzheimer’s disease, etc.
Bone marrow mononuclear cells have also been used for tissue engineering and scaffold-based regeneration studies in the case of bone and musculoskeletal disorders. Furthermore, these cells bypass the ethical regulations associated with using embryonic cells and induced pluripotent cells and are safe with minimal risk of therapeutic side effects. Despite the potential advantage of bone marrow mononuclear cells in cell therapy, the mechanisms of action and the differentiated specific cell type(s) are not well defined yet. While some researchers suggest that hematopoietic stem cells are responsible for the repair and regeneration of the damaged tissue in case of disorders, some researchers are of the opinion that a combination of mononuclear cells is required to have proper therapeutic effects. Therefore, further research and clinical studies are required to efficiently establish the importance of bone marrow mononuclear cells in the case of treating diseases as an alternative to conventional therapies.
At Kosheeka, we offer a wide selection of hematopoietic cells including mononuclear cells with tissue-specific, species-specific, and disease-specific customizations and we also provide a specified growth medium for your primary cell culture as per the client’s requirement. For more information or related inquiries, contact us at email@example.com.